ANAB Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 114253 min ago

@ $22.40

Išleistas: 13 vas. 2024 @ 16:30

Grąža: 17.59%

Ankstesnis signalas: vas. 12 - 16:36

Ankstesnis signalas: Pardavimas

Grąža: -3.80 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications...

Stats
Šios dienos apimtis	317 726
Vidutinė apimtis	361 357
Rinkos kapitalizacija	719.57M
EPS	$0 ( 2024-03-13 )
Kita pelno data	( $-1.540 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.33
ATR14	$0.0430 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-22	Faga Daniel	Sell	145 940	Common Stock
2024-03-25	Faga Daniel	Sell	3 000	Common Stock
2024-03-26	Faga Daniel	Sell	347 441	Common Stock
2024-02-16	Loumeau Eric J	Sell	5 000	Employee Stock Option (right to buy)
2024-02-16	Loumeau Eric J	Buy	5 000	Common Stock

INSIDER POWER
37.31
Last 98 transactions
Buy: 3 215 504 \| Sell: 1 263 529

Tūris Koreliacija

Ilgas: -0.17 (neutral)

Trumpas: -0.91 (very strong negative)

Signal:(25.755) Possible Trading Opportunity Present (swing)

AnaptysBio Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
CDXS	0.959
TRIP	0.957
ZD	0.956
SRTS	0.954
CSGS	0.953
ETSY	0.95
LGHL	0.944
HNNA	0.941
NMTR	0.94
VERI	0.94

10 Labiausiai neigiamai susiję koreliacijos
MSDA	-0.938
DHAC	-0.929
MCAA	-0.928
MYRG	-0.92
BRIV	-0.918
RELY	-0.917
SKYA	-0.917
BRIVU	-0.916
FICV	-0.914
ADAL	-0.914

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

AnaptysBio Inc Koreliacija - Valiuta/Žaliavos

-0.04
( neutral )

0.03
( neutral )

0.00
( neutral )

-0.39
( neutral )

0.50
( neutral )

-0.23
( neutral )

AnaptysBio Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$17.16M
Bruto pelnas:	$14.78M (86.15 %)
EPS:	$-6.08

FY	2023
Pajamos:	$17.16M
Bruto pelnas:	$14.78M (86.15 %)
EPS:	$-6.08

FY	2022
Pajamos:	$10.29M
Bruto pelnas:	$7.95M (77.30 %)
EPS:	$-4.57

FY	2021
Pajamos:	$63.18M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.11

Financial Reports:

No articles found.

AnaptysBio Inc

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.